The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium

  title={The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium},
  author={R. Rapkin and M. Creinin},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2403 - 2410}
Introduction: Neural tube defects are the second most common congenital anomaly in the United States, although their incidence may be decreased by periconception folic acid supplementation. A new oral contraceptive containing drospirenone and ethinyl estradiol plus levomefolate calcium was formulated to decrease the risk of neural tube defects in pregnancies conceived while taking or shortly after discontinuing this pill. Areas covered: Because of its novelty, very few studies have been… Expand
Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: A pooled analysis of three studies conducted in North America and Europe
E2V/DNG provides reliable contraceptive efficacy in women aged 18 to 50 years, and in the first 13 cycles of treatment, 76 to 81% of women experienced scheduled withdrawal bleeding, and 13 to 23% experienced intracyclic bleeding. Expand
Simultaneous Quantification of Drospirenone, Ethinyl Estradiol and Levomefolate by Stability Indicating RP-HPLC Method
A new sensitive, selective, precise and accurate stability indicating reverse phase high performance liquid chromatographic method has been developed for the simultaneous quantification ofExpand


Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder. Expand
Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives
Ethinylestradiol/drospirenone initiators and initiators of other oral contraceptives are similarly likely to experience thromboembolism. Expand
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone
The treatment was well tolerated with an excellent safety profile and the majority of women (86%) stated that they were satisfied or very satisfied with the treatment and over 70% of women would have continued with the study medication. Expand
A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
The COC 3-mg DRSP/20-microg EE 24/4 regimen COC is a suitable option for women with moderate acne vulgaris who require contraception. Expand
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
Based on the biochemical and pharmacodynamic data, drospirenone appears to be a viable alternative to the currently available progestogens. Expand
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
Risks of adverse cardiovascular and other serious events in users of a DRSP-containing OC are similar to those associated with the use of other OCs. Expand
The use of newer progestins for contraception.
Several new progestins have been designed to minimize side-effects related to androgenic, estrogenic or glucocorticoid receptor (GR) interactions, and Dienogest (DNG) and drospirenone (DRSP) exhibit a partial antiandrogenic action, and DRSP has predominant anti-mineraloc Corticoid properties. Expand
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Drospirenone/EE, given in a 24/4 regimen, was superior to placebo for improving symptoms associated with PMDD. Expand
Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Electrolyte disturbances, arrhythmia, syncope, myocardial infarction, and related clinical outcomes which could be caused by hyperkalemia during follow-up are verified. Expand
Treatment of Acne Using a 3-Milligram Drospirenone/20-Microgram Ethinyl Estradiol Oral Contraceptive Administered in a 24/4 Regimen: A Randomized Controlled Trial
The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne. Expand